Sanofi (SNY 1.07%) seems to march to a tune slightly different from the rest of the big pharmas. The company has focused on partnerships with biotechs (including owning significant equity stakes in Regeneron and Alnlyam) and some targeted acquisitions like Genzyme, to strengthen its portfolio and keep its growth strong into the future.
Apparently, the strategic differences that Sanofi has with the rest of big pharma will extend over to the current M&A blitz as well -- when asked about the strategic repositioning of the likes of Novartis (which recently purchased GlaxoSmithKline's oncology portfolio for up to $16 bilion), Sanofi CEO Chris Viehbacher said that "It doesn't really affect us."
Then again, Sanofi is rumored to be seeking to divest some of its drug portfolio for as much as $7 billion, so the company appears interested in joining in at least some of the industry's recent shake-up. In this segment from Tuesday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass dig more into Sanofi's business strategy and what investors should look for from this stock.
